What are ADC's

Our services

ADC Review
is made possible by:

NCT02213744 (HERMIONE) (Clinical Trial/ MM-302)

Study Title
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician’s Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients (HERMIONE) (NCT02213744)

Trial Description
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician’s choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer patients who have received prior treatment with trastuzumab in any setting and who have either progressed or are intolerant to each of pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting. Patients must not have been previously treated with an anthracycline in any setting.

This trial is sponsored by Merrimack Pharmaceuticals®

Study Data

  • Condition:
    • Breast Cancer
    • HER2 Positive Breast Cancer
  • Interventions:
    • Drugs used in this trial
      • MM-302
      • Gemcitabine
      • Capecitabine
      • Vinorelbine
      • Trastuzumab
  • Phase: II & III
  • Estimated Enrollment: 250
  • Start: July 2014
  • Completion: February 2017
  • Last updated: February 2016
  • Last verified: February 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: March 3, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar